Karim Rihawi
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers 8
- Colorectal Cancer Treatments and Studies 7
- Lung Cancer Research Studies 6
- Peptidase Inhibition and Analysis 5
- Cancer Research top 10%
- Cancer Genomics and Diagnostics 7
-
- Lung Cancer Treatments and Mutations 12
- Gastric Cancer Management and Outcomes 5
- Brain Metastases and Treatment 4
- Co-authors
- Alessandro RizzoFabiola Lorena Rojas LlimpeAngela Dalia RicciGiuseppe AprileGianpiero FasolaAndrea ArdizzoniRita GolfieriStefano Brocchi
- Journals
- Journal of Clinical Oncology (6 papers)PLoS ONE (1 paper)Clinical Cancer Research (1 paper)
- Partner nations
- ItalyUnited KingdomUkraine
In The Last Decade
Karim Rihawi
47 papers receiving 891 citations
Peers
Comparison fields: 5 of 96
- Oncology 452
- Cancer Research 174
- Pulmonary and Respiratory Medicine 369
- Immunology 133
- Gastroenterology 28
Countries citing papers authored by Karim Rihawi
This map shows the geographic impact of Karim Rihawi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karim Rihawi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karim Rihawi more than expected).
Fields of papers citing papers by Karim Rihawi
This network shows the impact of papers produced by Karim Rihawi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karim Rihawi. The network helps show where Karim Rihawi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Karim Rihawi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 6 | |
| 2 | 2022 | 10 | |
| 3 | 2021 | 4 | |
| 4 | 2021 | 4 | |
| 5 | 2020 | 11 | |
| 6 | 2018 | 15 | |
| 7 | 2018 | 35 | |
| 8 | 2017 | 2 | |
| 9 | 2017 | 1 | |
| 10 | 2017 | 2 | |
| 11 | 2016 | 26 | |
| 12 | 2016 | 0 | |
| 13 | 2015 | 28 | |
| 14 | 2015 | 19 | |
| 15 | 2015 | 26 | |
| 16 | 2015 | 27 | |
| 17 | 2015 | 5 | |
| 18 | 2015 | 3 | |
| 19 | 2014 | 22 | |
| 20 | 2014 | 34 |
About Karim Rihawi
Karim Rihawi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 50 papers that have together received 905 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (8 papers), Cancer Genomics and Diagnostics (7 papers), Colorectal Cancer Treatments and Studies (7 papers), Lung Cancer Research Studies (6 papers), Peptidase Inhibition and Analysis (5 papers), Gastric Cancer Management and Outcomes (5 papers) and Brain Metastases and Treatment (4 papers). The work is most often cited by research in Oncology (452 citations), Cancer Research (174 citations) and Pulmonary and Respiratory Medicine (369 citations). Karim Rihawi has collaborated with scholars based in Italy, United Kingdom and Ukraine. Frequent co-authors include Alessandro Rizzo, Fabiola Lorena Rojas Llimpe, Angela Dalia Ricci, Giuseppe Aprile, Gianpiero Fasola, Andrea Ardizzoni, Rita Golfieri, Stefano Brocchi, Giovanni Marasco and Matteo Renzulli. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.